title: Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapy.
abstract: BACKGROUND
  A large number of human tumor-associated antigens that are recognized by CD8(+) T cells in a human leukocyte antigen class I (HLA-I)-restricted fashion have been identified. Special AT-rich sequence binding protein 1 (SATB1) is highly expressed in many types of human cancers as part of their neoplastic phenotype, and up-regulation of SATB1 expression is essential for tumor survival and metastasis, thus this protein may serve as a rational target for cancer vaccines.
  
  
  RESULTS
  Twelve SATB1-derived peptides were predicted by an immuno-informatics approach based on the HLA-A*02 binding motif. These peptides were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from HLA-A*02(+) healthy donors and/or HLA-A*02(+) cancer patients. The recognition of HLA-A*02(+) SATB1-expressing cancer cells was also tested. Among the twelve SATB1-derived peptides, SATB1(565-574) frequently induced peptide-specific T cell responses in PBMCs from both healthy donors and cancer patients. Importantly, SATB1(565-574)-specific T cells recognized and killed HLA-A*02(+) SATB1(+) cancer cells in an HLA-I-restricted manner.
  
  
  CONCLUSIONS
  We have identified a novel HLA-A*02-restricted SATB1-derived peptide epitope recognized by CD8(+) T cells, which, in turn, recognizes and kills HLA-A*02(+) SATB1(+) tumor cells. The SATB1-derived epitope identified may be used as a diagnostic marker as well as an immune target for development of cancer vaccines.
authors: Center for Inflammation and Epigenetics, The Methodist Hospital Research Institute, Houston, Texas, USA.
authors: Mingjun
authors: M
authors: Wang
authors: Bingnan
authors: B
authors: Yin
authors: Satoko
authors: S
authors: Matsueda
authors: Lijuan
authors: L
authors: Deng
authors: Ying
authors: Y
authors: Li
authors: Wei
authors: W
authors: Zhao
authors: Jia
authors: J
authors: Zou
authors: Qingtian
authors: Q
authors: Li
authors: Christopher
authors: C
authors: Loo
authors: Rong-Fu
authors: RF
authors: Wang
authors: Helen Y
authors: HY
authors: Wang
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology; D045744:Cell Line, Tumor; D000939:Epitopes / Q000235:genetics / Q000276:immunology; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D036961:Matrix Attachment Region Binding Proteins / Q000235:genetics* / Q000276:immunology; D009369:Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D010455:Peptides / Q000235:genetics / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D000939:Epitopes; D015395:Histocompatibility Antigens Class I; D036961:Matrix Attachment Region Binding Proteins; D010455:Peptides; C076189:SATB1 protein, human